Skip to main content
ADMA BIOLOGICS, INC. logo

ADMA BIOLOGICS, INC. — Investor Relations & Filings

Ticker · ADMA ISIN · US0008991046 US Manufacturing
Filings indexed 962 across all filing types
Latest filing 2020-08-14 Director's Dealing
Country US United States of America
Listing US ADMA

About ADMA BIOLOGICS, INC.

https://www.admabiologics.com/

ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company that develops, manufactures, and commercializes specialty plasma-derived biologics. The company's portfolio features FDA-approved immune globulin (Ig) products for the treatment of immune-compromised patients and individuals at risk for certain infections. ADMA Biologics operates a vertically integrated manufacturing process for its specialty biologic products and utilizes a patented immunotechnology platform, which includes a proprietary microneutralization assay to measure neutralizing antibody levels in plasma. The company also offers contract manufacturing capabilities.

Recent filings

Filing Released Lang Actions
Director's Dealing 2020
Director's Dealing
2020-08-14 English
Director's Dealing 2020
Director's Dealing
2020-08-13 English
Director's Dealing 2020
Director's Dealing
2020-08-12 English
Director's Dealing 2020
Director's Dealing
2020-08-12 English
Director's Dealing 2020
Director's Dealing
2020-08-12 English
Capital/Financing Update 2020
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act of 1933. It details an offering of common stock up to $50 million through an Open Market Sale Agreement with Jefferies LLC. The text includes information about the offering terms, risk factors, use of proceeds, plan of distribution, and legal matters. It is a detailed disclosure document related to capital raising activities, specifically a shelf registration offering. This type of document is classified as a Capital/Financing Update (CAP) because it provides updates on the company's fundraising and capital structure changes. The document is lengthy (15,000 characters) and contains substantive information about the offering, not merely an announcement or a brief summary, so it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS).
2020-08-05 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.